Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19425824 | 0.93 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2HSD17B10TLR8 | |
| SCHEMBL21401193 | 0.89 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL23583995 | 0.88 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10TLR8 | |
| SCHEMBL22930725 | 0.87 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2HSD17B10TLR8 | |
| SCHEMBL21398242 | 0.86 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HSD17B10TLR8 | |
| SCHEMBL22930813 | 0.86 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HSD17B10TLR8 | |
| SCHEMBL18474327 | 0.82 | TLR8 (0.34) | TLR8 | |
| SCHEMBL22488080 | 0.81 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2HSD17B10TLR8 | |
| SCHEMBL22594525 | 0.79 | TLR8 (0.33) | TLR8 | |
| SCHEMBL19425843 | 0.77 | CNR2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | NPC1 3692/4885RAB9A 4696/4885SMN1; SMN2 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.